CelLBxHealth has reported full-year results for the year ended December 2025, with limited incremental information following two trading updates already provided in 2026. The focus now shifts to execution against its partner‑led strategy and the monetisation of strategic collaborations into sustainable revenue streams. With the previously announced corporate restructuring nearing completion, annualised operating cash costs are expected to reduce to c£6.7m, providing a cash runway into 2Q27 and s ....